Search

Displaying results 4071 - 4080 of 6951 in total
  1. Drug

    Chlorpromazine

    go.drugbank.com/drugs/DB00477
    ApprovedInvestigationalVet approved

    The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has s...

    Categories: Adrenergic alpha-1 Receptor Antagonists, Serotonin Receptor Antagonists
  2. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.

  3. Target

    Small ribosomal subunit protein RACK1

    go.drugbank.com/bio_entities/BE0008967
    TargetHumans

    Regulates internalization of the muscarinic receptor CHRM2. Promotes apoptosis by increasing oligomerization of BAX and disrupting the interaction of BAX with the anti-apoptotic factor BCL2L.

    Synonyms: Receptor for activated C kinase, Receptor for activated C kinase 1
  4. Drug

    FK352B

    go.drugbank.com/drugs/DB06484
    Experimental

    FK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.

  5. Drug

    Atovaquone

    go.drugbank.com/drugs/DB01117
    ApprovedInvestigational

    Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.

    Categories: Antibiotics for Pneumocystis Pneumonia
  6. Drug

    AER001

    go.drugbank.com/drugs/DB05078
    Investigational

    AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.

  7. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain. … AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.

  8. Drug

    N4-Hydroxycytidine

    go.drugbank.com/drugs/DB15660
    Experimental

    [A193014] The prodrug of N4-hydroxycytidine, [EIDD-2801], is also being investigated for its broad spectrum activity against the coronavirus family of viruses.[A193014]

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Pegsunercept

    go.drugbank.com/drugs/DB06611
    Investigational

    Pegsunercept is used for treating rheumatoid arthritis. Phase II clinical trials were completed in January 2010.

  10. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    The results showed potent inhibition of the target, suggesting that GC-373 holds therapeutic potential for Covid-19[A219036].

    Categories: Experimental Unapproved Treatments for COVID-19